Anti-phospho-MAP Kinase Kinase 1/2 (pSer217/221) antibody produced in rabbit

affinity isolated antibody, buffered aqueous glycerol solution

Anti-phospho-MEK 1/2 (pSer217/221)
MDL number:
Pricing and availability is not currently available.

biological source


Quality Level

antibody form

affinity isolated antibody

antibody product type

primary antibodies




buffered aqueous glycerol solution

mol wt

antigen 45 kDa

species reactivity

human, mouse, rat


flow cytometry: 1:50 using PMA treated human peripheral blood lymphocytes and Jurkat cells.
immunocytochemistry: 1:1,000 using HeLa cells
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100 using tissue sections from human breast carcinoma
immunoprecipitation (IP): 1:50
western blot: 1:1,000 using serum-treated NIH-3T3 cells



UniProt accession no.

shipped in

wet ice

storage temp.


Gene Information

human ... MAPK1(5594)
mouse ... Mapk1(26413)
rat ... Mapk1(116590)

General description

MAP Kinase Kinase (MAPKK, MEK1 and MEK2) belong to a family of enzymes that activates their substrate by dual phosphorylation at threonine and tyrosine residues. MEK1 and MEK2 have 86% homology in their catalytic domain. Activation of MEK1/2 is mediated in mitogen-stimulated cells by Raf-1 kinase. MEK1/2 then activates ERK1/2 leading to the activation of several downstream targets that contribute to cell proliferation, apoptosis and motility. In addition to ERK1/2, there may be non-catalytic effectors of MEK1/2. MEK isoforms appear to be widely expressed in the central nervous system, thymus, spleen, heart, lung, and kidney. Active forms of MEK1/2 are sufficient for the transformation of NIH3T3 cells of the differentiation of PC-12 cells.
The antibody specifically recognizes MEK1/2 (45 kDa) only when phosphorylated at Ser217 and Ser221. It reacts strongly with MEK1/2 phosphorylated only at Ser217, but less when phosphorylated only at Ser221. It shows not cross reaction with any other related family members including SEK.


Detects MEK 1/2 when phosphorylated at Ser217 and Ser221. It does not react with non-phosphorylated MEK 1/2, SEK (MKK4), MKK3, or MKK6.


synthetic phosphopeptide Ser217/221 corresponding to residues around Ser217/221 of human MEK 1/2.


Anti-phospho-MAP Kinase Kinase 1/2 (MEK1/2) has a wide range of applications. The recommended working dilution for immunoblotting in serum treated NIH3T3 cells is 1:1000. For immunoprecipitation, a working dilution of 1:50 may be used. For detection by immunohistochemistry in paraffin-embedded human breast carcinoma sections, antibody dilution of 1:100 may be used. For immunocytochemistry (immunofluorescence), in HeLa cells, a working dilution of 1:1000 may be used.

Physical form

Solution in 10 mM HEPES, pH 7.5, containing 150 mM sodium chloride, 100 μg/ml bovine serum albumin and 50% glycerol.


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


NONH for all modes of transport

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Hyukjin Cha et al.
The Biochemical journal, 378(Pt 3), 857-865 (2003-12-13)
Phosphorylation-specific antibodies provide a powerful tool for analysing the regulation and activity of proteins in the MAP (mitogen-activated protein) kinase and other signalling pathways. Using synchronized cells, it was observed that phosphorylation-specific antibodies developed against the active form of MKK1/MKK2...
S Cowley et al.
Cell, 77(6), 841-852 (1994-06-17)
The MAP kinase pathway is activated by a wide variety of external signals leading to cell proliferation or differentiation. However, it is not clear whether activation of this pathway is required for cellular responses or whether it is only one...
Kazi M Ahmed et al.
Molecular cancer research : MCR, 4(12), 945-955 (2006-12-26)
The molecular mechanism by which tumor cells increase their resistance to therapeutic radiation remains to be elucidated. We have previously reported that activation of nuclear factor-kappaB (NF-kappaB) is causally associated with the enhanced cell survival of MCF+FIR cells derived from...
Christophe Frémin et al.
Journal of hematology & oncology, 3, 8-8 (2010-02-13)
The Ras-dependent Raf/MEK/ERK1/2 mitogen-activated protein (MAP) kinase signaling pathway is a major regulator of cell proliferation and survival. Not surprisingly, hyperactivation of this pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine kinases...
Theodosia Charitou et al.
British journal of cancer, 121(1), 37-50 (2019-05-28)
Activating mutations in KRAS frequently occur in colorectal cancer (CRC) patients, leading to resistance to EGFR-targeted therapies. To better understand the cellular reprogramming which occurs in mutant KRAS cells, we have undertaken a systems-level analysis of four CRC cell lines...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.